Review top news and interview highlights from the week ending August 9, 2024.
CGTLive®’s Weekly Rewind
Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The trial evaluating the safety and tolerability of IDP-023 will be led by Stanford and UCSF.
The cofounder and chief science officer of Longeveron discussed working to show potential benefits in a follow-up phase 3 trial.
A recent study also recommended a shorter, more flexible monitoring period post-CAR–T therapy.
The chief medical officer at Creyon Bio discussed findings from a treated patient with a TNP02 missense mutation.
BriaCell initiated the pivotal phase 3 BRIA-ABC trial in October 2023.
Keys to a Successful Cell and Gene Therapy Launch
February 16th 2025The success of cell and gene therapies relies not just on approvability but on affordability and accessibility. Innovative manufacturing, automation, and digital tools are key to expanding patient access and ensuring commercial viability.